A diversity of experience to take our products from the laboratory to the clinic and on to commercialisation

Dr Victoria Gordon brings to QBiotics Group a sound scientific background combined with broad business management experience and a strong commercial emphasis. She left her position as a research scientist in chemical ecology with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to establish EcoBiotics Pty Ltd (EcoBiotics) in 2000, followed by QBiotics Pty Ltd in 2004. Victoria also governed the merger of EcoBiotics and QBiotics to form the QBiotics Group in 2017. Victoria has been Managing Director and CEO of EcoBiotics/the QBiotics Group since their inception. Victoria’ recent additional board experience includes Non-Executive Director of Biopharmaceuticals Australia and Non-Executive Director and Non-Executive Chairman of the Australian Rainforest Foundation. Victoria’s relevant committee memberships include two consecutive terms of the Queensland Government Biotechnology Advisory Council, Federal Government Expert Forum on Biomedicine, Federal Government Expert Forum on Environmental Biotechnology, and the Queensland Government Science Education Taskforce. In 2004 Dr Gordon was presented an award by the Queensland Premier for her service to the biotechnology industry.

Victoria has broad experience in the management of commercial research for Boral Timber Division, then one of Australia’s largest plantation forestry companies, has owned and managed a number of small businesses and has held lecturing positions in industrial mycology and plant tissue culture at the University of Tasmania.

Dr Gordon holds a PhD in Microbiology, Bachelor of Applied Science in Chemistry and Biology (Honours), Diplomas in Human and Animal Health, and is a Graduate of the Australian Institute of Company Directors.

Dr Gordon is a Director of the QBiotics Group Limited, EcoBiotics Pty Ltd, QBiotics Pty Ltd, QBiotics Netherlands and QBiotics UK.

Dr Reddell brings to the Company expert scientific knowledge combined with extensive practical experience in leadership, resourcing, management and commercialisation of complex multi-institutional research and development projects. Dr Reddell is co-founder of EcoBiotics and QBiotics and has been CSO of both companies since their inception.

Prior to co-founding EcoBiotics in 2000, Dr Reddell gained an international reputation for his scientific expertise in tropical forest ecology and management. During that time, he held senior leadership positions as a Senior Principal Research Scientist and Program Leader at CSIRO’s Tropical Forest Research Centre and later as Principal Plant Ecologist for an environmental consulting business in the Rio Tinto group of companies.

Dr Reddell holds a PhD in Forest Ecology and a Bachelor of Science (1A Honours) from the University of Western Australia. He has been a Fellow of the Australian Institute of Company Directors since 2007.

Dr Reddell is a Director of QBiotics Group and its subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

Mr Wenzel has worked for EcoBiotics and QBiotics since 2011. Prior to this, Michael worked for over 13 years in the audit and advisory divisions of KPMG. During this time, Michael gained a wealth of experience across a range of industries, including biotechnology, as a senior engagement manager, key client contact, and quality control reviewer on a variety of external and internal audits of publicly listed companies, unlisted companies, foreign owned subsidiaries, government entities and not-for-profit entities.

Michael holds a Bachelor of Commerce, is a Registered Company Auditor, a Certified Internal Auditor and an Associate Member of Chartered Accountants Australia and New Zealand and the Institute of Internal Auditors – Australia. Michael is a Certificated Member of the Governance Institute of Australia and a Graduate Member of the Australian Institute of Company Directors.

Dr Schmidt has considerable expertise in the development of drug candidates for submission to both the TGA in Australia and the FDA in the USA up to Clinical Phase III including preparation of CMC and Preclinical data packages required for IND submissions, and the clinical practices required during Clinical Phase I and II trials.

Peter’s human drug development expertise complements and strengthens QBiotics veterinary drug development team. Peter came to QBiotics from the drug discovery and development company Xenome Limited where he was Director of CMC and Preclinical Drug Development for 6 years. Prior to Xenome, Peter was Senior Scientist at Agen Biomedical for 7 years and Professional Officer at Radiopharmaceuticals Australian Nuclear Science and Technology Organisation for 8 years.

Peter holds a Bachelor of Science (Honours) and a PhD in Experimental Medicine.

Ms Phipps has extensive experience in marketing and commercialisation of pharmaceutical and animal health brands spanning more than 25 years.

Mary has held senior management and business roles with Novartis Animal Health for 15 years including Head of Sales ANZ, Marketing Director Therapeutics Brands USA, Marketing Director Sentinel USA, Marketing Manager Companion Animals ANZ and Business Unit Head Companion Animals ANZ. Prior to Novartis Mary was employed by Novogen, Alcon and Sanofi Aventis.

Mary holds a Bachelor of Business and Masters of Commerce (both with marketing majors).

Richard has extensive life science/healthcare experience, comprising nearly 27 years of industry experience in clinical drug development combined with 11 years of clinical practice in Internal Medicine.

Richard has a proven track record of success in new product approvals, with diverse experience comprising small molecule drugs, large molecule biologics, and device development; all phases of clinical development, including multiple IND submissions; Phase I, II, III, and IV trials, investigator-initiated studies, and lifecycle management; multinational clinical trials; NDA and MAA preparations and submissions; post-marketing pharmacovigilance; and dozens of successful face-to-face meetings with regulatory agencies across a range of therapeutic areas. As a seasoned industry consultant, Richard has assisted numerous small to large pharmaceutical companies. He previously held clinical development leadership positions at Sophiris Bio Corp, Rockwell Medical Technologies, Halozyme Therapeutics, Chugai Pharma USA, Ligand Pharmaceuticals, and Gensia.

Richard holds a Bachelor of Arts degree in Chemistry (Summa Cum Laude) from Dartmouth College, an MD from Johns Hopkins University, is board-certified in general Internal Medicine, and has authored/co-authored 59 manuscripts and scientific abstracts and posters.

Dr Pamela Jones has over 30 years’ experience in veterinary roles, including almost 20 years specialising in veterinary oncology. Pamela has completed residencies in both medical and radiation oncology and has contributed to many articles published and presented at numerous veterinary conferences and meetings in relation to those areas. In Pamela’s roles with Aratana Therapeutics she firstly worked as Veterinary Medical Liaison, producing the content and materials to educate vets and staff on novel therapeutics. Pamela then worked as an Immuno-Oncology Advisory Board Member, where she provided consulting advice in relation to novel anti-cancer agents, clinical trials and therapeutic pipelines, as well as being a primary advisor and clinical consultant for specific products. Pamela has also continued to practice in the veterinary space, offering her services as a radiation oncologist through PetCure Oncology.

Pamela holds a Bachelor of Science (Cum Laude) in Zoology and a Doctor of Veterinary Medicine (Cum Laude).

Dr Mynott has worked for QBiotics since 2019 and has 30 years’ experience in drug development and technology transfer in academia and the biotechnology industry. During Tracey’s career she has gained broad knowledge and experience in initiating and conducting fundamental biological research, drug discovery and project management, as well as devising and implementing drug development and clinical programs, licensing and intellectual property protection and business strategies. 

Having co‐founded four biotechnology companies, Tracey has experience in strategic and operational matters, risk management, legal, due diligence, and compliance issues, capital raising and investor relations. In Tracey’s previous role at Anatara, she devised, secured strategic partnerships and executed the development plan for its lead product Detach^® through to its marketing approval and a global licensing deal with Zoetis, Inc.

Tracey holds a Bachelor of Agricultural Science (Honours) and a PhD in Pathogenesis of Enteric Infections.

Ms Cleal has worked on QBiotics projects since 2016. A seasoned pharmaceutical professional, Andrea has over 30 years’ experience in international drug development.

Specialising in clinical development Andrea’s experience includes head office (Glaxo R&D) and local market activities (Schering UK, Glaxo Australia). Andrea has been involved in all phases of product development from laboratory, through multinational clinical research management and strategic medical marketing activities. Andrea established and ran Australasian operations for a Nasdaq listed CRO (ClinTrials Research Inc) which specialised in clinical development and data management services across a broad range of therapeutic areas, and subsequently a consultancy business providing services to the pharmaceutical, biotechnology and affiliated industries. Andrea is experienced in working with a range of business’ including big pharma and small to large biotechnology companies across a broad range of therapeutic indications including difficult to treat and orphan diseases.

Andrea holds Bachelor of Science (Honours) in Biomedical Science and a Masters of Business- Enterprise Innovation.